Dr. Lucica Ditiu, Executive Secretary of the Stop TB Partnership, noted: "With this new focus, The Lilly MDR-TB Partnership will have a significant impact on two of the most critical challenges to tackling MDR-TB: the shortage of expertise and health workers – especially community health workers – who are well versed in all the medical and social elements of TB care; and the uncertain supply of high-quality second-line TB drugs. By supporting partners that are addressing these challenges, The Lilly MDR-TB Partnership will continue to help countries move toward providing high-quality TB treatment for all people who need it."
The Lilly MDR-TB Partnership
The Lilly MDR-TB Partnership is comprised of more than 25 health organizations, academic institutions and corporations – including the World Health Organization, the Stop TB Partnership and the International Council of Nurses. The goal of the partnership is to combat the expanding global crisis of MDR-TB by providing access to medicines, raising awareness and training health care professionals.
"Years ago, Lilly began supplying two medicines since shown to be effective against MDR-TB," said Lechleiter. "Even as our portfolio evolved over time to a focus on chronic diseases, we started The Lilly MDR-TB Partnership to mobilize and engage organizations to fight this devastating disease. Since the inception of the partnership in 2003, our goal has been to collaborate with other organizations and help them advance this work, with Lilly's involvement diminishing over time in a responsible manner."
Significant Successes 2003 - 2011
In the first eight years of The Lilly MDR-TB Partnership (2003 – 2011), Lilly's commitment of US $135 million was allocated among three principal areas: US $70 million for drug supply and the transfer of MDR-TB drug manufacturing technology to local suppliers
|SOURCE Eli Lilly and Company|
Copyright©2010 PR Newswire.
All rights reserved